Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis

Andrea Baggiano, Michele Boldrini, Ana Martinez-Naharro, Tushar Kotecha, Aviva Petrie, Tamer Rezk, Maurizio Gritti, Cristina Quarta, Daniel S. Knight, Ashutosh D. Wechalekar, Helen J. Lachmann, Stefano Perlini, Gianluca Pontone, James C. Moon, Peter Kellman, Julian D. Gillmore, Philip N. Hawkins, Marianna Fontana

Research output: Contribution to journalArticle

Abstract

Objectives: This study aimed to assess the diagnostic use of native T1 to detect cardiac amyloidosis (CA) in a large prospective cohort of patients referred for suspected systemic amyloidosis. Background: CA is a progressive and fatal underdiagnosed cause of heart failure. Cardiovascular magnetic resonance (CMR) has emerged as an extremely useful test for the non-invasive diagnosis of CA, but administration of contrast is still required to make a diagnosis. Methods: In this study, 868 patients with suspected CA referred between 2015 and 2017 underwent CMR with late gadolinium enhancement (LGE), T1 mapping, and an array of clinical investigations. Results: The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. T1 was significantly elevated in both types of CA and this was associated with high diagnostic accuracy in the overall population (area under the curve, 0.93). A native T1 <1,036 ms was associated with 98% negative predictive value for CA whereas a native T1 >1,164 ms was associated with 98% positive predictive value for CA. We propose the use of these cut-offs to exclude or confirm CA and to restrict the administration of contrast only to patients with intermediate probability (native T1 between 1,036 and 1,164 ms), 58% of patients in this population. Conclusions: Native myocardial T1 enables diagnosis of CA to be made without need for gadolinium contrast in a large proportion of patients with suspected systemic amyloidosis. We propose a diagnostic algorithm for non-contrast CMR applicable to patients with suspected amyloidosis.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalJACC: Cardiovascular Imaging
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Amyloidosis
Magnetic Resonance Spectroscopy
Gadolinium
Population
Area Under Curve
Heart Failure
Light

Keywords

  • accuracy
  • amyloidosis
  • cardiovascular magnetic resonance
  • native T1 mapping
  • renal failure

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Baggiano, A., Boldrini, M., Martinez-Naharro, A., Kotecha, T., Petrie, A., Rezk, T., ... Fontana, M. (2020). Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 13(1), 69-80. https://doi.org/10.1016/j.jcmg.2019.03.026

Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. / Baggiano, Andrea; Boldrini, Michele; Martinez-Naharro, Ana; Kotecha, Tushar; Petrie, Aviva; Rezk, Tamer; Gritti, Maurizio; Quarta, Cristina; Knight, Daniel S.; Wechalekar, Ashutosh D.; Lachmann, Helen J.; Perlini, Stefano; Pontone, Gianluca; Moon, James C.; Kellman, Peter; Gillmore, Julian D.; Hawkins, Philip N.; Fontana, Marianna.

In: JACC: Cardiovascular Imaging, Vol. 13, No. 1, 01.2020, p. 69-80.

Research output: Contribution to journalArticle

Baggiano, A, Boldrini, M, Martinez-Naharro, A, Kotecha, T, Petrie, A, Rezk, T, Gritti, M, Quarta, C, Knight, DS, Wechalekar, AD, Lachmann, HJ, Perlini, S, Pontone, G, Moon, JC, Kellman, P, Gillmore, JD, Hawkins, PN & Fontana, M 2020, 'Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis', JACC: Cardiovascular Imaging, vol. 13, no. 1, pp. 69-80. https://doi.org/10.1016/j.jcmg.2019.03.026
Baggiano, Andrea ; Boldrini, Michele ; Martinez-Naharro, Ana ; Kotecha, Tushar ; Petrie, Aviva ; Rezk, Tamer ; Gritti, Maurizio ; Quarta, Cristina ; Knight, Daniel S. ; Wechalekar, Ashutosh D. ; Lachmann, Helen J. ; Perlini, Stefano ; Pontone, Gianluca ; Moon, James C. ; Kellman, Peter ; Gillmore, Julian D. ; Hawkins, Philip N. ; Fontana, Marianna. / Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. In: JACC: Cardiovascular Imaging. 2020 ; Vol. 13, No. 1. pp. 69-80.
@article{c0fbfe0a6d5748d48be503bd720f3f47,
title = "Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis",
abstract = "Objectives: This study aimed to assess the diagnostic use of native T1 to detect cardiac amyloidosis (CA) in a large prospective cohort of patients referred for suspected systemic amyloidosis. Background: CA is a progressive and fatal underdiagnosed cause of heart failure. Cardiovascular magnetic resonance (CMR) has emerged as an extremely useful test for the non-invasive diagnosis of CA, but administration of contrast is still required to make a diagnosis. Methods: In this study, 868 patients with suspected CA referred between 2015 and 2017 underwent CMR with late gadolinium enhancement (LGE), T1 mapping, and an array of clinical investigations. Results: The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. T1 was significantly elevated in both types of CA and this was associated with high diagnostic accuracy in the overall population (area under the curve, 0.93). A native T1 <1,036 ms was associated with 98{\%} negative predictive value for CA whereas a native T1 >1,164 ms was associated with 98{\%} positive predictive value for CA. We propose the use of these cut-offs to exclude or confirm CA and to restrict the administration of contrast only to patients with intermediate probability (native T1 between 1,036 and 1,164 ms), 58{\%} of patients in this population. Conclusions: Native myocardial T1 enables diagnosis of CA to be made without need for gadolinium contrast in a large proportion of patients with suspected systemic amyloidosis. We propose a diagnostic algorithm for non-contrast CMR applicable to patients with suspected amyloidosis.",
keywords = "accuracy, amyloidosis, cardiovascular magnetic resonance, native T1 mapping, renal failure",
author = "Andrea Baggiano and Michele Boldrini and Ana Martinez-Naharro and Tushar Kotecha and Aviva Petrie and Tamer Rezk and Maurizio Gritti and Cristina Quarta and Knight, {Daniel S.} and Wechalekar, {Ashutosh D.} and Lachmann, {Helen J.} and Stefano Perlini and Gianluca Pontone and Moon, {James C.} and Peter Kellman and Gillmore, {Julian D.} and Hawkins, {Philip N.} and Marianna Fontana",
year = "2020",
month = "1",
doi = "10.1016/j.jcmg.2019.03.026",
language = "English",
volume = "13",
pages = "69--80",
journal = "JACC: Cardiovascular Imaging",
issn = "1936-878X",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis

AU - Baggiano, Andrea

AU - Boldrini, Michele

AU - Martinez-Naharro, Ana

AU - Kotecha, Tushar

AU - Petrie, Aviva

AU - Rezk, Tamer

AU - Gritti, Maurizio

AU - Quarta, Cristina

AU - Knight, Daniel S.

AU - Wechalekar, Ashutosh D.

AU - Lachmann, Helen J.

AU - Perlini, Stefano

AU - Pontone, Gianluca

AU - Moon, James C.

AU - Kellman, Peter

AU - Gillmore, Julian D.

AU - Hawkins, Philip N.

AU - Fontana, Marianna

PY - 2020/1

Y1 - 2020/1

N2 - Objectives: This study aimed to assess the diagnostic use of native T1 to detect cardiac amyloidosis (CA) in a large prospective cohort of patients referred for suspected systemic amyloidosis. Background: CA is a progressive and fatal underdiagnosed cause of heart failure. Cardiovascular magnetic resonance (CMR) has emerged as an extremely useful test for the non-invasive diagnosis of CA, but administration of contrast is still required to make a diagnosis. Methods: In this study, 868 patients with suspected CA referred between 2015 and 2017 underwent CMR with late gadolinium enhancement (LGE), T1 mapping, and an array of clinical investigations. Results: The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. T1 was significantly elevated in both types of CA and this was associated with high diagnostic accuracy in the overall population (area under the curve, 0.93). A native T1 <1,036 ms was associated with 98% negative predictive value for CA whereas a native T1 >1,164 ms was associated with 98% positive predictive value for CA. We propose the use of these cut-offs to exclude or confirm CA and to restrict the administration of contrast only to patients with intermediate probability (native T1 between 1,036 and 1,164 ms), 58% of patients in this population. Conclusions: Native myocardial T1 enables diagnosis of CA to be made without need for gadolinium contrast in a large proportion of patients with suspected systemic amyloidosis. We propose a diagnostic algorithm for non-contrast CMR applicable to patients with suspected amyloidosis.

AB - Objectives: This study aimed to assess the diagnostic use of native T1 to detect cardiac amyloidosis (CA) in a large prospective cohort of patients referred for suspected systemic amyloidosis. Background: CA is a progressive and fatal underdiagnosed cause of heart failure. Cardiovascular magnetic resonance (CMR) has emerged as an extremely useful test for the non-invasive diagnosis of CA, but administration of contrast is still required to make a diagnosis. Methods: In this study, 868 patients with suspected CA referred between 2015 and 2017 underwent CMR with late gadolinium enhancement (LGE), T1 mapping, and an array of clinical investigations. Results: The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. T1 was significantly elevated in both types of CA and this was associated with high diagnostic accuracy in the overall population (area under the curve, 0.93). A native T1 <1,036 ms was associated with 98% negative predictive value for CA whereas a native T1 >1,164 ms was associated with 98% positive predictive value for CA. We propose the use of these cut-offs to exclude or confirm CA and to restrict the administration of contrast only to patients with intermediate probability (native T1 between 1,036 and 1,164 ms), 58% of patients in this population. Conclusions: Native myocardial T1 enables diagnosis of CA to be made without need for gadolinium contrast in a large proportion of patients with suspected systemic amyloidosis. We propose a diagnostic algorithm for non-contrast CMR applicable to patients with suspected amyloidosis.

KW - accuracy

KW - amyloidosis

KW - cardiovascular magnetic resonance

KW - native T1 mapping

KW - renal failure

UR - http://www.scopus.com/inward/record.url?scp=85074036593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074036593&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2019.03.026

DO - 10.1016/j.jcmg.2019.03.026

M3 - Article

C2 - 31202744

AN - SCOPUS:85074036593

VL - 13

SP - 69

EP - 80

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

SN - 1936-878X

IS - 1

ER -